Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

被引:25
|
作者
Kitasato, Lisa [1 ]
Tojo, Taiki [1 ,2 ]
Hatakeyama, Yuko [2 ]
Kameda, Ryo [1 ]
Hashikata, Takehiro [1 ]
Yamaoko-Tojo, Minako [1 ,3 ,4 ]
机构
[1] Kitasato Univ, Grad Sch Med Sci, Sagamihara, Kanagawa 228, Japan
[2] Kitasato Univ, Sch Med, Dept Cardioangiol, Sagamihara, Kanagawa 228, Japan
[3] Kitasato Univ, Special Dept Cardiac Rehabil & Prevent Cardiovasc, Sch Med, Sagamihara, Kanagawa 228, Japan
[4] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Minami Ku, Sagamihara, Kanagawa 2520373, Japan
关键词
Atherosclerosis; Endothelial function; Cardiovascular disease prevention; OXIDATIVE STRESS GENERATION; IMPAIRED GLUCOSE-TOLERANCE; CROSS-SECTIONAL RELATIONS; CORONARY-HEART-DISEASE; SENSITIVE K+ CHANNEL; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; NITRIC-OXIDE; RISK-FACTORS; INSULIN-SECRETION;
D O I
10.1186/1475-2840-11-79
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients. However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients. These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide
    Lisa Kitasato
    Taiki Tojo
    Yuko Hatakeyama
    Ryo Kameda
    Takehiro Hashikata
    Minako Yamaoka-Tojo
    Cardiovascular Diabetology, 11
  • [2] Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
    Toru Hiyoshi
    Mutsunori Fujiwara
    Zemin Yao
    TheJournalofBiomedicalResearch, 2019, 33 (01) : 1 - 16
  • [3] Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
    Hiyoshi, Toru
    Fujiwara, Mutsunori
    Yao, Zemin
    JOURNAL OF BIOMEDICAL RESEARCH, 2019, 33 (01): : 1 - 16
  • [4] Carbohydrate restriction with postmeal walking effectively mitigates postprandial hyperglycemia and improves endothelial function in type 2 diabetes
    Francois, Monique E.
    Myette-Cote, Etienne
    Bammert, Tyler D.
    Durrer, Cody
    Neudorf, Helena
    DeSouza, Christopher A.
    Little, Jonathan P.
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2018, 314 (01): : H105 - H113
  • [5] Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus
    Inoue, Masahiro
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2257 - 2268
  • [6] The Effects of DPP-4 Inhibitor and Postprandial Hyperglycemia on Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus
    Kusama, Minoru
    Watarai, Atsuko
    Kawamura, Takahiko
    Kanai, Akio
    Imamine, Rui
    Kouchi, Yu
    Kawai, Mariko
    Minatoguchi, Makiko
    Mizoguchi, Asako
    Nakashima, Eitaro
    Hotta, Nigishi
    DIABETES, 2014, 63 : A609 - A609
  • [7] Sustained Improvement of Postprandial Endothelial Function in Type 2 Diabetes With Exenatide
    Koska, Juraj
    Liu, James
    Raravikar, Kalyani
    Schwenke, Dawn C.
    Schwartz, Eric A.
    Reaven, Peter D.
    DIABETES, 2013, 62 : A311 - A311
  • [8] PREDICTORS OF POSTPRANDIAL HYPERGLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES
    Nita, C. A.
    Rusu, A.
    Bala, C. G.
    Hancu, N.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2009, 5 (02) : 177 - 182
  • [9] METOCLOPRAMIDE AS A RISK FACTOR FOR POSTPRANDIAL HYPERGLYCEMIA IN TYPE 2 DIABETES
    Gutierrez-Hermosillo, H.
    Diaz de Leon-Gonzalez, E.
    Beltran Santiago, D.
    Armando Cedillo-Rodriguez, J.
    Gutierrez Hermosillo, V.
    Tamez-Perez, H. E.
    NUTRICION HOSPITALARIA, 2012, 27 (04) : 1267 - 1271
  • [10] Postprandial hyperglycemia in type 2 diabetes and obstructive sleep apnea
    Aurora, R. Nisha
    Punjabi, Naresh M.
    SLEEP MEDICINE, 2021, 84 : 173 - 178